Recipharm pharmaservices is a finished-dose manufacturer based in India. It appears in 3 regulatory filings across 3 regulators, without an active US DMF or CEP on file. Its filings concentrate with BOMRA (BW), NAFDAC (NG) and NPRA (MY). Its GMP standing is certified by EMA, CDSCO (India) and MFDS (Korea), among 5 authorities. Its most recent recorded inspection, by US FDA, closed on 22 March 2024 as NAI. Customs aggregates show $11.0M of exports covering 587 molecules to 14 destinations in 2025.
NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.
| Site | FDA FEI |
|---|---|
| Bengaluru, India | 3009150119 |
| NELAMANGALA, India | Not on file |
| Bengaluru, India | Not on file |
| bengaluru 562 123, India | Not on file |
| Regulator | Filings | GMP certificates |
|---|---|---|
| BOMRA (BW) | 1 | None |
| NAFDAC (NG) | 1 | None |
| NPRA (MY) | 1 | None |
| EMA | None | 4 |
| CDSCO (India) | None | 3 |
| MFDS (Korea) | None | 2 |
| US FDA | None | 1 |
| ANVISA (Brazil) | None | 1 |
| Year | Revenue | Exports | Destinations |
|---|---|---|---|
| 2026 YTD | Not reported | $2.4M | 10 |
| 2025 | Not reported | $11.0M | 14 |
| 2024 | Not reported | $7.3M | 17 |
| 2023 | Not reported | $9.0M | 15 |
Export figures are customs aggregates. We do not publish the identity of any buyer.
Answered from this company's own record. Where a register holds nothing, the question is not asked rather than answered with a zero. How we count our figures.
Choose your molecules and target markets. Recipharm pharmaservices comes back tiered against every other supplier able to file there.
Start for freeRanked by shared active ingredients where we have them, otherwise by country and comparable credentials.